On June 30, 2026, US patient advocacy groups highlighted the growing role of international sourcing under FDA Personal Importation policies to combat the high financial toxicity of oncology therapies. Purchasing high-precision therapies like Keytruda (Pembrolizumab) or Herceptin (Trastuzumab) directly in the United States often results in high out-of-pocket costs, even for insured patients.

At Onco Medicine, we support American patient choice by supplying original, verified oncology medications. Sourcing from authorized global distributors helps reduce costs by 30% to 70% while maintaining the highest standard of quality control.

FDA Personal Importation Standards

• Personal Import Policy: The FDA allows personal importation of prescription medicines under specific conditions, including when the drug is for a serious condition, there is no commercialization of the drug by the importer, and the patient has a valid US prescription.
• Cost Optimization: Sourcing through validated international channels bypasses domestic retail markups, helping patients maintain treatment adherence.
• Cold-Chain Integrity: All biological shipments to the USA are packed in GDP-certified containers equipped with temperature loggers to confirm stability upon arrival.

Reducing financial toxicity is key to successful treatment. Onco Medicine ensures transparent pricing, reliable customs clearance, and end-to-end tracking for US patients seeking affordable access to advanced cancer care.